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Site-selective cyclic AMP analogs bind to site 1 or site 2 of the known cAMP-binding sites depending on 
the position of substituents on the purine ring, either at C-2 and C-8 (site 1) or at C-6 (site 2). The growth 
inhibitory effect of such site-selective cAMP analogs used in this investigation with 15 human cancer cell 
lines surpassed that of analogs previously tested. The most potent analogs were 8-chloro, N%benzyl and 
N6-phenyl-8-p-chlorophenyithio-cAMP. The combination of a C-8 with an N 6 analog had synergistic effects. 
The 24 site-selective analogs tested produced growth inhibition ranging from 30 to 80% at micromolar con- 
centrations with no sign of toxic effects. Growth inhibition was not due to a block in a specific phase of 
the cell cycle but paralleled achange in cell morphology, an increase of the R H cAMP receptor protein and 
a decrease of p21 ras protein. Since the adenosine counterpart ofthe 8-chloro analog produced G l synchro- 
nization without affecting the R I! and p21 ras protein levels, it is unlikely that an adenosine metabolite is
involved in the analog effect. Site-selective cAMP analogs thus provide a new biological tool for control 
of cancer growth. 
Cyclic AMP; Protein kinase; Proto-oncogene; (Human cancer line) 
1. INTRODUCTION 
Cyclic adenosine 3 ' ,5 ' -monophosphate (cAMP) 
has been implicated as a regulatory agent in cell 
growth and differentiation [1-4], but its precise 
role has not yet been uncovered, cAMP in mam- 
malian cells functions by binding to its receptor 
protein, cAMP-dependent protein kinase [5,6]. 
Two distinct isozymes, type I and type II protein 
kinases, have been identified [7,8], and differential 
expression of these isozymes has been linked to the 
regulation of cell growth and differentiation 
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[9-12]. Since a mixture of type I and type II kinase 
isozymes is present in most tissues [7,8], selective 
modulation of these isozymes in intact cells may be 
a crucial function of cAMP. 
Both isozymes contain dimeric regulatory (R) 
subunits and two catalytic (C) subunits [7,8]. The 
R subunits (R I, R n) of type I and type II isozymes 
differ, but the C subunits of isozymes are identical 
[7,8]. Both R I and R n contain two types of binding 
sites for cAMP, site 1 and site 2 [13,14], and 
cAMP analogs that selectively bind to either one of 
the two sites are known as site 1 selective (C-2, C-8 
analogs) and site 2 selective (C-6 analogs), respec- 
tively [13,14]. 
Site-selective analogs in appropriate combina- 
tions demonstrate synergism of binding and 
specificity toward either type I or type II kinases 
[15,16]. Application of these in vitro findings on 
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the site-selective analogs to cAMP effects in vivo in 
intact cells or tissues has been scarce [17-19]. 
Therefore, we investigated the effect of site- 
selective cAMP analogs on the growth of human 
cancer lines of various cell types. 
2. MATERIALS AND METHODS 
cAMP, N 6,O 2'-dibutyryl-cAMP (DBcAMP) 
and 8-Br-cAMP were from Boehringer Mannheim 
(Indianapolis, IN). All other cAMP analogs were 
synthesized [20] at the Nucleic Acid Research In- 
stitute (Costa Mesa, CA). 
The human cancer cell lines used included 
MCF-7, MCF-7ras, MDA-MB-231, T-47D, 
ZR-75-1, BT-20 and HBL-100 breast cancers; 
WiDr, LS-174T and HT-29 colon carcinomas; 
A549 lung carcinoma; HT-1080 fibrosarcoma; 
A4573 Ewing's sarcoma; FOG and U251 gliomas. 
All breast cancer cell lines were grown in improved 
minimal essential medium supplemented with 10°70 
fetal bovine serum (FBS), 20 mM Hepes, 
penicillin-streptomycin and extra glutamine; colon 
carcinoma cell lines and A549 and HT-1080 cell 
lines were grown in Eagle's minimal essential 
medium supplemented with 10% FBS, Eagle's 
minimal essential medium non-essential amino 
acids, 20 mM Hepes, extra glutamine and 
penicillin-streptomycin. A4573 cell line was grown 
in RPMI supplemented with glutamine, penicillin- 
streptomycin, 20 mM Hepes and 10% FBS. FOG 
and U251 cell lines were grown in Dulbecco's 
modified minimal essential medium supplemented 
with penicillin-streptomycin, glutamine, 20 mM 
Hepes and 10070 FBS. All cells were grown at 37°C 
in humidified incubators in an atmosphere of 5070 
CO2. 
For cell growth experiments, 2-3 × 105 ceUs/60 
mm dish were seeded, and 24 h later (day 0), the 
medium was removed, and fresh medium and the 
additives were added then and every 48 h 
thereafter. The cAMP analogs were added using 
100× concentrated stock solutions. As desired 
times, cell counts in duplicate were performed on 
a Coulter counter after harvesting cells with gentle 
trypsinization. 
Cell extracts were prepared at 0-4°C. The cell 
pellets (2 × l07 cells), after two washes with 
phosphate-buffered saline, were suspended in 0.5 
ml buffer Ten (0.1 M NaC1, 5 mM MgCl2, 1% 
Nonidet P-40, 0.5% Na deoxycholate, 2 KIU/ml 
bovine aprotinin and 20 mM Tris-HCl, pH 7.4), 
vortex-mixed, passed through a 22-gauge needle 10 
times, allowed to stand for 30 min at 4°C, and cen- 
trifuged at 750 × g for 20 min; the resulting super- 
natants were used as cell lysates. 
3. RESULTS AND DISCUSSION 
Various site-selective cAMP analogs, C-2, C-6 
and C-8 monosubstituted and C-2 and C-8 or C-6 
and C-8 disubstituted, were tested for their effect 
on the growth of cancer lines. Table 1 shows values 
for the growth inhibitory effect of 24 cAMP 
analogs. The values for percentage growth inhibi- 
tion were determined from dose-response curve ex- 
periments. The analogs are listed in order from the 
most to the least potent for growth inhibition for 
a given modification on the adenine ring. In breast 
(MCF-7 and MCF-7ras) and colon (LS-174T) 
cancer cell lines, analogs modified with a halogen 
or thio moiety at the C-8 position were more po- 
tent than those modified with an amino moiety at 
the C-8 position. Thus, at 50 #M, 8-C1-, 
8-thiomethyl- and 8-Br-cAMP exhibited 40-8007o 
growth inhibition, while 8-amino-~-hydroxyethyl-, 
8-aminomethyl- and 8-N,N-dimethylamino-cAMP 
exhibited growth inhibition of < 20%. Halogen or 
thio derivatives of C-8 analogs have generally 
greater specificity for type II protein kinase activa- 
tion, while amino derivatives of C-8 analogs 
demonstrate greater specificity for type I protein 
kinase activation [15,16]. Our data showing the 
greater growth inhibition by C-8 halogen or thio 
derivatives than C-8 amino derivatives suggest the 
involvement of the cellular type II protein kinase in 
growth inhibition. C-6 analogs were generally less 
potent in growth inhibition than the C-8 analogs. 
At 50 /zM, N6-benzyl - and N6-carbonylethoxy - 
cAMP demonstrated 30-70°70 growth inhibition. 
Dibutyryl-cAMP, at 50 #M, exhibited no growth 
inhibition of either breast or colon cancer cells. 
The C-6,-8 analog, N6-phenyl-8-thio-p - 
chlorophenyl-cAMP, having structural similarity 
within both N6-benzyl-cAMP (the most potent C-6 
analog) and 8-CI-cAMP (the most potent C-8 
analog), exhibited the greatest potency among the 
disubstituted analogs tested, whereas the analogs 
with a structural similarity in only one of the two 
positions, such as N6-n-butyl-8-thio-p-chloro - 
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Table 1 
Effect of site-selective cAMP analogs on the growth of breast (MCF-7, MCF-7ras) and colon (LS-174T) cancer cell lines 
Cyclic nucleotide analog: 
abbreviated name 
°7o growth inhibition at 50/~M 
MCF-7 MCF-7ras LS-174T 
C-8 8-chloro 67 80 75 
8-thiomethyl 46 48 42 
8-bromo 41 47 40 
8-iodo 26 28 25 
8-thio-p-chlorophenyl 23 22 24 
8-amino-/3-hydroxyethyl 15 15 20 
8-aminomethyl 14 18 15 
8-N,N-dimethylamino 0 0 0 
C-6 N6-benzyl 56 65 70 
N6-carbonylethoxy 32 42 40 
N6-benzoyl 30 33 28 
N6-carbamoylphenyl 10 20 0 
N6-butyryl 0 0 0 
N6,O 2' -dibutyryl 0 0 0 
C-2 2-n-hexyl 36 25 42 
2-thiobenzyl 28 30 22 
2-phenyi 10 15 15 
C-6,-8 N6-phenyl-8-thio-p-chlorophenyl 60 55 47 
N6,N6-diethyl-8-thio-p-chlorophenyl 43 43 45 
6-piperidino-8-thio-p-chlorophenyl 33 30 25 
N6-benzyl-8-thiobenzyl 25 30 20 
N6-n-butyl-8-thio-p-chlorophenyl 15 20 25 
C-2,-8 2-n-butyl-8-bromo 46 37 36 
2-methyl-8-thio-p-chlorophenyl 30 36 22 
The values of percentage growth inhibition were determined from dose-response curve experiments. Each value 
represents an average value obtained from three or more separate xperiments. Cell counting was performed on days 
3 and 4 
phenyl-cAMP or N°-benzyl-8-thiobenzyl-cAMP, 
exhibited less potency. C-2 analogs and C-2,-8 
analogs tested here were in general ess potent. 
8-C1-, N6-benzyl - and N6-phenyl-8-thio-p-chlo - 
rophenyl-cAMP were the three most potent growth 
inhibitors for all 15 cancer cell lines. These analogs 
at 20 #M demonstrated 40-76°70 growth inhibition 
(table 2). Thus, the site-selective cAMP analogs ex- 
erted a potent growth inhibition in a wide spectrum 
of human cancer cell lines: hormone-dependent 
(MCF-7, T-47D, ZR-75-1 [21]) and hormone- 
independent (MDA-MB-231, MCF-7ras, BT-20 
[22,23]) breast cancer lines, colon and lung cancer 
lines, f ibrosarcoma and glioma cell lines. The ma- 
jority of these cancer cell lines have shown a 
resistance to dibutyryl-cAMP treatment, even at 1 
mM, and to cAMP phosphodiesterase inhibitors. 
Previous studies have demonstrated that binding 
of  a cAMP analog selective for either intrachain 
site on the regulatory subunit of  protein kinase 
stimulates binding of a cAMP analog selective for 
the other site [24,25], and two such site-selective 
analogs in combination demonstrate synergism in 
protein kinase activation [15,16]. 
To test the effect of cAMP analog combina- 
tions, C-8 analog (site 1 selective) and C-6 analog 
(site 2 selective) were combined such that alone 
they exhibit growth inhibition of 10-20% each, 
and the effects were quantified by synergism quo- 
tient [16,17]. Synergism quotient was defined as 
the net growth inhibitory effect of the analog com- 
bination divided by the sum of the net individual 
analog effects on growth inhibition. The results 
showed that, in both breast and colon cancer lines, 
8-CI-cAMP (1 /~M) in combination with either 
N6-benzyl - (0.5 /~M) or N6-benzoyl-cAMP (0.5 
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Table 2 
Growth inhibition of human cancer cell lines by site-selective cAMP analogs 
October 1987 
% growth inhibition at 20/~M 
Cell line 8-C1 N6-Benzyl N6-Phenyl-8-thio - 
p-chlorophenyl 
Breast cancer MCF-7 65 (60-70) 50 (42-60) 57 (55-60) 
MCF-7ras 75 (70-80) 60 (55-70) 50 (45-55) 
MDA-MB-231 60 (54-63) 52 (44-56) 42 (36-52) 
T-47D 52 (44-60) 50 (45-55) 55 (45-60) 
ZR-75-1 51 (42-57) 53 (46-60) 55 (45-60) 
BT-20 54 (45-65) 42 (37-52) 53 (45-60) 
HBL-100 47 (40-52) 53 (48-59) 41 (36-55) 
Colon cancer LS-174T 70 (64-75) 60 (55-65) 45 (42-52) 
WiDr 68 (65-78) 62 (52-70) 46 (35-50) 
HT-29 70 (62-80) 45 (43-48) 48 (38-56) 
Lung cancer A549 71 (65-79) 60 (50-70) 51 (41-61) 
Fibrosarcoma HT-1080 56 (45-60) 55 (45-65) 40 (35-50) 
Ewing's sarcoma A4573 60 (55-70) 62 (50-72) 52 (47-55) 
Glioma FOG 60 (55-65) 76 (66-81) 62 (53-70) 
U251 45 (40-50) 60 (55-65) 60 (55-65) 
The values for percentage growth inhibition were determined from dose-response curve experiments and represent an 
average value and range (in parentheses) obtained for each analog from three or more separate xperiments. Cell 
counting was performed on days 3 and 4 
/zM) produced the greatest degree of growth inhibi- 
tion compared with that expected from the sum of 
the individual analogs alone (synergism quotient 
= 1.66-1.77). The combination, therefore, pro- 
duced growth inhibition equivalent to that shown 
by 10-15 #M of either analog alone. The N 6 
analogs also demonstrated synergism of growth in- 
hibition with other C-8 analogs, such as 
8-thiomethyl-cAMP (synergism quotient = 
1.50-1.87) and 8-Br-cAMP (synergism quotient = 
1.5). Only a limited degree of synergism was ex- 
pressed, however, when the N 6 analogs were com- 
bined with 8-amino derivatives (synergism quotient 
= 1.08-1.25). Bovine heart type II and rat heart 
type I protein kinases exhibit a different C-8 
analog specificity for stimulation of binding and 
synergism of activation when combined with a C-6 
analog [15,16]. Specifically, when used in com- 
bination with a C-6 analog, those analogs with 
sulfur or halogen attached to C-8 act more 
synergistically for type II protein kinase, and type 
I kinase exhibits greater synergism using analogs 
with nitrogen attached at C-8 [15,16]. Our results, 
showing that the synergism of growth inhibition by 
N 6 analogs when combined with 8-thio and 8-C1 
analogs far exceeds that by N 6 analogs in combina- 
tion with 8-amino derivatives, suggest a response 
of type II protein kinase present in the cancer ceils. 
The hormone-dependent and -independent 
breast, colon and lung cancer cells, and fibrosar- 
coma and glioma cells all demonstrated a 
characteristic change in their cell morphology after 
treatment with 8-C1- or N6-benzyl-cAMP at 10-20 
/~M for 4-5 days. The cells exhibited enlargement 
of the cytoplasm with a stretched fibroblast-like 
appearance (not shown). Thus, growth inhibition 
produced by the site-selective analogs brought 
about a change in cell morphology. 
Using a propidium iodide staining method [26], 
we examined whether the reduced cell proliferation 
observed in the cancer cell lines after treatment 
with the analogs was due to a specific block in one 
phase of the cell cycle. The results showed that the 
fractions of cells in G~, S and G2/M phases were 
not appreciably different between control cells (un- 
treated) and those treated with 8-CI-cAMP. Thus, 
the inhibition of cell growth induced by the cAMP 
analogs was not associated with a specific block in 
one phase of the cell cycle. However, 8-CI- 
adenosine treatment induced an appreciable in- 
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crease in G~ with a marked reduction in S phase of 
the cell population. These data indicated that the 
growth inhibition produced by 8-CI-cAMP treat- 
ment was not due to its adenosine metabolite. 
It has been considered that the type I isozyme of 
cAMP-dependent protein kinase is involved in cell 
proliferation and transformation, while type II 
isozyme is involved in cell differentiation and in- 
hibition of cell growth [9-12]. Since the type I and 
type II protein kinases differ only in their 
regulatory subunits (the cAMP-binding receptor 
protein) [7,8], we measured, using the photoaffini- 
ty ligand 8-N3-[32p]cAMP [27], the cAMP receptor 
protein during the analog treatment of these cancer 
cells. As shown in fig. 1A, the untreated breast 
A MDA-MB-231 LS-174T 
68K ... jR I I  
43K - ~ - - -  -- if" --_i." " -~R ! 
w 
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Fig. 1. The effect of site-selective cAMP analog treat- 
ment on the levels of cAMP receptor proteins and p21 
ras  protein. (A) Photoactivated incorporation of 
8-N3-[32p]cAMP; (B), Western blotting of p21 protein. 
R I, the 48 kDa R ~ cAMP receptor protein; R H, the 56 
kDa R H cAMP receptor protein; V, cell lysate from Ha- 
MuSV-transformed NIH 3T3 clone 13-3B-4 [18]. Lanes 
1-3, cells, each treated for 3 days with 8-CI-cAMP (10 
/zM), N6-benzyl-cAMP (20 ttM) and N6,O2'-dibutyryl- 
cAMP (1 mM), respectively; lane 4, untreated control 
cells; M, marker proteins of known molecular mass 
(Bethesda Research Laboratories). Each lane contained 
100 ttg protein for SDS-PAGE. The photoactivated in-
corporation of 8-Nr[32p]cAMP was performed as in 
[27] at cAMP exchange condition of 23°C for 60 min, 
and the samples were then subjected to SDS-PAGE. 
Western blotting of p21 protein was performed on the 
cell iysate as described [31,32] using p21 monoclonal n- 
tiserum Y13-259 [33]. To provide a reference p21, a cell 
lysate from Ha-MuSV-transformed NIH 3T3 clone 
13-3B-4 [18] was used. 
(MDA-MB-231) and colon (LS-174T) cancer cells 
contained a major cAMP receptor protein of 48 
kDa (lane 4), the R I cAMP receptor protein (the 
regulatory subunit of type I protein kinase) [5]. 
When the cells were treated for 3 days with 8-CI- 
cAMP (lane 1) or N6-benzyl-cAMP (lane 2), the 52 
kDa R H (the regulatory subunit of type II protein 
kinase) [28,29] increased appreciably with con- 
comitant decrease of the R E receptor protein. 
When the cells were treated with dibutyryl-cAMP, 
which did not appreciably inhibit cell growth, the 
R 1 and R n receptor levels remained unchanged (cf. 
lanes 3,4). Quantification by densitometric trac- 
ings of the autoradiograms showed that the site- 
selective analog treatments brought about a 
70-80°70 decrease in the R 1 level and a 10-12-fold 
increase in the R n receptor level, resulting in a 
4-9-fold increase in the ratio of R n to R I. These 
results were further confirmed with DEAE- 
cellulose chromatography of the cell extracts. 
Treatment with 8-CI-cAMP induced an increase of 
both R H and type II protein kinase holoenzyme 
with concomitant decrease of R x and type I protein 
kinase holoenzyme (not shown). 
The changing levels of the R x and R I~ cAMP 
receptor proteins paralleled a reduction of the 
cellular transforming gene product, p21 ras  protein 
[30], as measured by Western blotting analysis. As 
shown in fig.lB, treatment with 8-CI-cAMP (lane 
1) or N6-benzyl-cAMP (lane 2) caused a decrease 
in p21 ras  protein level, whereas dibutyryl-cAMP 
(lane 3), which did not affect cell growth, caused 
no reduction in the p21 level. Thus, the same C-6 
and C-8 analogs caused a decrease in the R E cAMP 
receptor and p21 protein levels and an increase in 
the R n cAMP receptor level. 
The changes in R ~, R ~t, and p21 levels were not 
found in the growth-arrested cells treated with 
8-Cl-adenosine. Thus, 8-Cl-adenosine failed to 
produce the biochemical change induced by 
8-CI-cAMP. 
To our knowledge, our data represent the first 
unequivocal demonstration that site-selective 
cAMP analogs are capable of exerting a major ef- 
fect on the growth of a spectrum of human cancer 
cell lines. We have shown that the site-selective 
analogs are effective at micromolar concentra- 
tions. All previously reported studies of cAMP 
regulation of cell growth, using dibutyryl-cAMP 
derivatives, reported effective concentrations in
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the unphysiologic millimolar range [1-3]. The 
analogs appear to work directly through the cAMP 
receptor protein, cAMP-dependent protein kinase 
present in the cells, by substituting endogenous 
cellular cAMP as recently demonstrated in rat 
hepatocytes [34] and rat heart and fat cells [351. 
Among the site-selective analogs tested, 8-CI- 
cAMP, which has a high site 1 selectivety for type 
II protein kinase (90-fold over that of cAMP; 
Ogreid, D., personal communication), exhibited 
the most potency in all cancer lines tested. In fact, 
an increase in the R n cAMP receptor protein with 
a decrease in the R ~ receptor protein correlated 
with the growth inhibitory potency of the analogs. 
This unique behavior of the site-selective analogs, 
demonstrating selective modulation of the R ~ and 
R H cAMP receptor proteins in cancer cells, is not 
mimicked by the early known analogs, such as 
dibutyryl-cAMP, cAMP itself or agents that in- 
crease cellular cAMP level, cAMP at high levels, 
having no site selectivity, activates both type I and 
type II protein kinase isozymes maximally and 
equally without discrimination [5-8]. 
The synergistic effect of the C-6 and C-8 analog 
combinations demonstrated on growth inhibition 
provides further support for analog efficacy being 
dependent on its ability to activate selectively type 
II protein kinase. However, the analogs could vary 
considerably in their cell penetration rate, 
phosphodiesterase sensitivity, and in other proper- 
ties that could also contribute to their potencies. 
The grown inhibitory effect of the site-selective 
cAMP analogs was not due to the cytotoxic effect 
of its adenosine metabolites as experimentally 
documented using 8-Cl-adenosine. Thus, the 
growth inhibitory effect of site-selective cAMP 
analogs as described here is different from that in 
previous reports, which have shown strong 
cytotoxicity by some of the amino-substituted C-8 
analogs [36] and cyclic nucleotides of purine 
analogs [37]. 
Growth inhibition produced by the analogs 
brought about biochemical and morphological 
changes but did not produce G1 arrest in the cancer 
cells tested here. Therefore, the analogs may pro- 
duce growth inhibition by slowing down the cell 
cycle progression and perhaps promoting cell dif- 
ferentiation. In fact, the role of site-selective 
cAMP analogs in the promotion of differentiation 
has been shown in leukemic cell lines [38]. 
The site-selective analogs were able to arrest he 
growth of cancer cells that are resistant to 
dibutyryl-cAMP. Therefore, the site-selective 
cAMP analogs tested here may be of use as growth 
inhibitors for a wide spectrum of cancer cells, in- 
cluding those previously found to be resistant o 
other cAMP analogs or to agents that increase in- 
tracellular cAMP. 
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